Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL
Authors
Zelenetz, A. D.Jurczak, W.
Ribrag, V.
Linton, Kim M
Collins, G. P.
Lopez-Jimenez, J.
Reddy, N.
Mengarelli, A.
Phillips, T. J.
Musuraca, G.
Sheehy, O.
Li, J.
Xu, W.
Azoulay, M. M.
Ghalie, R.
Zinzani, P. L.
Affiliation
Memorial Sloan Kettering Cancer Center, New York, NYIssue Date
2022
Metadata
Show full item recordCitation
Zelenetz AD, Jurczak W, Ribrag V, Linton K, Collins GP, Lopez-Jimenez J, et al. Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301972.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.7511Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.7511Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.7511